MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells

Breast Cancer Research

Volumn 14, Issue 1, 2012, Pages

  Lappano, Rosamaria ^a   Santolla, Maria F ^a   Pupo, Marco ^a   Sinicropi, Maria S ^a   Caruso, Anna ^a   Rosano, Camillo ^b   Maggiolini, Marcello ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

(ETHYL 3 [5 (2 ETHOXYCARBONYL 1 METHYLVINYLOXY) 1 METHYL 1H INDOL 3 YL]BUT 2 ENOATE); ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR ALPHA; G PROTEIN COUPLED RECEPTOR 30; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; ANTIESTROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA, HUMAN; ETHYL 3 (5 (2 ETHOXYCARBONYL 1 METHYLVINYLOXY) 1 METHYL 1H INDOL 3 Y)BUT 2 ENOATE; ETHYL 3-(5-(2-ETHOXYCARBONYL-1-METHYLVINYLOXY)-1-METHYL-1H-INDOL-3-Y)BUT-2-ENOATE; G PROTEIN COUPLED RECEPTOR; GPER PROTEIN, HUMAN; INDOLE DERIVATIVE;

ARTICLE; BREAST CANCER; CELL GROWTH; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG BINDING; DRUG MECHANISM; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOLECULAR MODEL; SIGNAL TRANSDUCTION; BINDING COMPETITION; BINDING SITE; BREAST TUMOR; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; METABOLISM; MOLECULAR DOCKING; NEOPLASM; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN MOTIF; PROTEIN PROCESSING; PROTEIN TERTIARY STRUCTURE; TRANSCRIPTION INITIATION;

AMINO ACID MOTIFS; ANTINEOPLASTIC AGENTS, HORMONAL; BINDING SITES; BINDING, COMPETITIVE; BREAST NEOPLASMS; CELL PROLIFERATION; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; INDOLES; MCF-7 CELLS; MOLECULAR DOCKING SIMULATION; NEOPLASMS, HORMONE-DEPENDENT; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION;

EID: 84855767653     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3096     Document Type: Article

References (61)

1. Deroo BJ, Korach KS. Estrogen receptors and human disease. J Clin Invest 2006, 116:561-570. 10.1172/JCI27987, 2373424, 16511588.
2. Ascenzi P, Bocedi A, Marino M. Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol Aspects Med 2006, 27:299-402. 10.1016/j.mam.2006.07.001, 16914190.
3. Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991, 151:67-72. 10.1001/archinte.1991.00400010089011, 1824675.
4. Scott JA, McGuire WL. New molecular markers of prognosis in breast cancer. Endocrine-Dependent Tumors 1991, 179-196. New York: Raven Press, Voigt K-D, Knabbe C.
5. Ponzone R, Biglia N, Jacomuzzi ME, Mariani L, Dominguez A, Sismondi P. Antihormones in prevention and treatment of breast cancer. Ann NY Acad Sci 2006, 1089:143-158. 10.1196/annals.1386.037, 17261763.
6. Herynk MH, Fuqua SA. Estrogen receptors in resistance to hormone therapy. Adv Exp Med Biol 2007, 608:130-143. 10.1007/978-0-387-74039-3_10, 17993238.
7. Maggiolini M, Picard D. The unfolding stories of GPR30, a new membrane bound estrogen receptor. J Endocrinol 2010, 204:105-114. 10.1677/JOE-09-0242, 19767412.
8. Filardo EJ, Quinn JA, Bland KI, Frackelton AR. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 2000, 14:1649-1660. 10.1210/me.14.10.1649, 11043579.
9. Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, Pezzi V, Montanaro D, Musti AM, Picard D, Andò S. The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem 2004, 279:27008-27016. 10.1074/jbc.M403588200, 15090535.
10. Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005, 146:624-632.
11. Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, Andò S, Maggiolini M. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17β-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol 2006, 20:631-646.
12. Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A, Oprea TI, Prossnitz ER, Musti AM, Andò S, Maggiolini M. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res 2007, 67:1859-1866. 10.1158/0008-5472.CAN-06-2909, 17308128.
13. Vivacqua A, Bonofiglio D, Albanito L, Madeo A, Rago V, Carpino A, Musti AM, Picard D, Andò S, Maggiolini M. 17β-Estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the G protein coupled-receptor GPR30. Mol Pharmacol 2006, 70:1414-1423. 10.1124/mol.106.026344, 16835357.
14. Chan QK, Lam HM, Ng CF, Lee AY, Chan ES, Ng HK, Ho SM, Lau KM. Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest. Cell Death Differ 2010, 17:1511-1523. 10.1038/cdd.2010.20, 2897932, 20203690.
15. Chevalier N, Bouskine A, Fenichel P. Role of GPER/GPR30 in tumoral testicular germ cells proliferation. Cancer Biol Ther 2011, 12:2-3. 10.4161/cbt.12.1.15726, 21508670.
16. Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA, Steinhoff MM, Sabo E. Distribution of GPR30, a seven membrane-spanning estrogen receptor in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin Cancer Res 2006, 12:6359-6366. 10.1158/1078-0432.CCR-06-0860, 17085646.
17. Smith HO, Leslie KK, Singh M, Qualls CR, Revankar CM, Joste NE, Prossnitz ER. GPR30: a novel indicator of poor survival for endometrial carcinoma. Am J Obstet Gynecol 2007, 196:386.e1-9. discussion 386.e9-e11.
18. Smith HO, Arias-Pulido H, Kuo DY, Howard T, Qualls CR, Lee SJ, Verschraegen CF, Hathaway HJ, Joste NE, Prossnitz ER. GPR30 predicts poor survival for ovarian cancer. Gynecol Oncol 2009, 114:465-471. 10.1016/j.ygyno.2009.05.015, 2921775, 19501895.
19. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005, 307:1625-1630. 10.1126/science.1106943, 15705806.
20. Prossnitz ER, Maggiolini M. Mechanisms of estrogen signaling and gene expression via GPR30. Mol Cell Endocrinol 2009, 308:32-38. 10.1016/j.mce.2009.03.026, 2847286, 19464786.
21. Quinn JA, Graeber CT, Frackelton AR, Kim M, Schwarzbauer JE, Filardo EJ. Coordinate regulation of estrogen-mediated fibronectin matrix assembly and epidermal growth factor receptor transactivation by the G protein-coupled receptor, GPR30. Mol Endocrinol 2009, 23:1052-1064. 10.1210/me.2008-0262, 2703602, 19342448.
22. Albanito L, Sisci D, Aquila S, Brunelli E, Vivacqua A, Madeo A, Lappano R, Pandey DP, Picard D, Mauro L, Andò S, Maggiolini M. Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells. Endocrinology 2008, 149:3799-3808. 10.1210/en.2008-0117, 2488235, 18467441.
23. Vivacqua A, Lappano R, De Marco P, Sisci D, Aquila S, De Amicis F, Fuqua SA, Andò S, Maggiolini M. G protein-coupled receptor 30 expression is up-regulated by EGF and TGF alpha in estrogen receptor alpha-positive cancer cells. Mol Endocrinol 2009, 23:1815-1826. 10.1210/me.2009-0120, 19749156.
24. Pandey DP, Lappano R, Albanito L, Madeo A, Maggiolini M, Picard D. Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J 2009, 28:523-532. 10.1038/emboj.2008.304, 2657575, 19153601.
25. Albanito L, Lappano R, Madeo A, Chimento A, Prossnitz ER, Cappello AR, Dolce V, Abonante S, Pezzi V, Maggiolini M. G-protein-coupled receptor 30 and estrogen receptor-alpha are involved in the proliferative effects induced by atrazine in ovarian cancer cells. Environ Health Perspect 2008, 116:1648-1655. 10.1289/ehp.11297, 2599758, 19079715.
26. Madeo A, Maggiolini M. Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol-induced gene expression and migration in breast cancer-associated fibroblasts. Cancer Res 2010, 70:6036-6046. 10.1158/0008-5472.CAN-10-0408, 20551055.
27. Thomas P, Dong J. Binding and activation of the seven-transmembrane estrogen receptor GPR30 by environmental estrogens: a potential novel mechanism of endocrine disruption. J Steroid Biochem Mol Biol 2006, 102:175-179. 10.1016/j.jsbmb.2006.09.017, 17088055.
28. Lappano R, Rosano C, De Marco P, De Francesco EM, Pezzi V, Maggiolini M. Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells. Mol Cell Endocrinol 2010, 320:162-170. 10.1016/j.mce.2010.02.006, 20138962.
29. Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS, Parker MA, Tkachenko SE, Savchuck NP, Sklar LA, Oprea TI, Prossnitz ER. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol 2006, 2:207-212. 10.1038/nchembio775, 16520733.
30. Dennis MK, Field AS, Burai R, Ramesh C, Petrie WK, Bologa CG, Oprea TI, Yamaguchi Y, Hayashi SI, Sklar LA, Hathaway HJ, Arterburn JB, Prossnitz ER. Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity. J Steroid Biochem Mol Biol 2011, 127:358-366. 10.1016/j.jsbmb.2011.07.002, 21782022.
31. Ramesh C, Nayak TK, Burai R, Dennis MK, Hathaway HJ, Sklar LA, Prossnitz ER, Arterburn JB. Synthesis and characterization of iodinated tetrahydroquinolines targeting the G protein-coupled estrogen receptor GPR30. J Med Chem 2010, 53:1004-1014. 10.1021/jm9011802, 2818973, 20041667.
32. Eiler S, Gangloff M, Duclaud S, Moras D, Ruff M. Overexpression, purification, and crystal structure of native ERα LBD. Protein Expr Purif 2001, 22:165-173. 10.1006/prep.2001.1409, 11437591.
33. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998, 95:927-937. 10.1016/S0092-8674(00)81717-1, 9875847.
34. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem 2004, 25:1605-1612. 10.1002/jcc.20084, 15264254.
35. Potdar MK, Mohile SS, Salunkhe MM. Coumarin syntheses via Pechmann condensation in Lewis acidic chloroaluminate ionic liquid. Tetrahedron Lett 2001, 42:9285-9287.
36. Subhas Bose D, Rudradas AP, Hari Babu M. The indium(III) chloridecatalyzed von Pechmann reaction: a simple and effective procedure for the synthesis of 4-substituted coumarins. Tetrahedron Lett 2002, 43:9195-9197.
37. Lappano R, Recchia AG, De Francesco EM, Angelone T, Cerra MC, Picard D, Maggiolini M. The cholesterol metabolite 25-hydroxycholesterol activates estrogen receptor α-mediated signaling in cancer cells and in cardiomyocytes. PLoS One 2011, 6:e16631. 10.1371/journal.pone.0016631, 3031608, 21304949.
38. Maggiolini M, Recchia AG, Carpino A, Vivacqua A, Fasanella G, Rago V, Pezzi V, Briand PA, Picard D, Andò S. Oestrogen receptor beta is required for androgen-stimulated proliferation of LNCaP prostate cancer cells. J Mol Endocrinol 2004, 32:777-791. 10.1677/jme.0.0320777, 15171712.
39. Lanzino M, Sisci D, Morelli C, Garofalo C, Catalano S, Casaburi I, Capparelli C, Giordano C, Giordano F, Maggiolini M, Andò S. Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells--identification of a novel androgen response element. Nucleic Acids Res 2010, 38:5351-5365. 10.1093/nar/gkq278, 2938215, 20421209.
40. Altucci L, Addeo R, Cicatiello L, Dauvois S, Parker MG, Truss M, Beato M, Sica V, Bresciani F, Weisz A. 17β-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 1996, 12:2315-2324.
41. Morelli C, Garofalo C, Bartucci M, Surmacz E. Estrogen receptor-alpha regulates the degradation of insulin receptor substrates 1 and 2 in breast cancer cells. Oncogene 2003, 22:4007-4016. 10.1038/sj.onc.1206436, 12821935.
42. Coughlin SS, Ekwueme DU. Breast cancer as a global health concern. Cancer Epidemiol 2009, 33:315-318. 10.1016/j.canep.2009.10.003, 19896917.
43. Gaskell DJ, Hawkins RA, Sangsterl K, Chetty U, Forrest APM. Relation between immunocytochemical estimation of oestrogen receptor in elderly patients with primary breast cancer and response to tamoxifen. Lancet 1989, 1:1044-1046.
44. Mason BH, Holdaway TM, Mullins PR, Yee LH, Kay RG. Progesterone and estrogen receptors as prognostic variables in breast cancer. Cancer Res 1983, 43:2985-2990.
45. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011, 62:233-247. 10.1146/annurev-med-070909-182917, 20887199.
46. Rugo HS. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Ann Oncol 2008, 19:16-27.
47. Kurebayashi J. Resistance to endocrine therapy in breast cancer. Cancer Chemother Pharmacol 2005, 56:39-46.
48. Lappano R, Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov 2011, 10:47-60. 10.1038/nrd3320, 21193867.
49. El Zein N, D'Hondt S, Sariban E. Crosstalks between the receptors tyrosine kinase EGFR and TrkA and the GPCR, FPR, in human monocytes are essential for receptors-mediated cell activation. Cell Signal 2010, 22:1437-1447. 10.1016/j.cellsig.2010.05.012, 20566383.
50. Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E, Auricchio F. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 1996, 15:1292-1300. 450032, 8635462.
51. Castoria G, Migliaccio A, Bilancio A, Di Domenico M, de Falco A, Lombardi M, Fiorentino R, Varricchio L, Barone MV, Auricchio F. PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J 2001, 20:6050-6059. 10.1093/emboj/20.21.6050, 125704, 11689445.
52. Castoria G, Migliaccio A, Di Domenico M, Lombardi M, de Falco A, Varricchio L, Bilancio A, Barone MV, Auricchio F. Role of atypical protein kinase C in estradiol-triggered G1/S progression of MCF-7 cells. Mol Cell Biol 2004, 24:7643-7653. 10.1128/MCB.24.17.7643-7653.2004, 506976, 15314172.
53. Migliaccio A, Di Domenico M, Castoria G, Nanayakkara M, Lombardi M, de Falco A, Bilancio A, Varricchio L, Ciociola A, Auricchio F. Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action. Cancer Res 2005, 65:10585-10593. 10.1158/0008-5472.CAN-05-0912, 16288052.
54. Levin ER. Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol 2003, 17:309-317. 10.1210/me.2002-0368, 12554774.
55. Migliaccio A, Castoria G, Di Domenico M, Ciociola A, Lombardi M, De Falco A, Nanayakkara M, Bottero D, De Stasio R, Varricchio L, Auricchio F. Crosstalk between EGFR and extranuclear steroid receptors. Ann N Y Acad Sci 2006, 1089:194-200. 10.1196/annals.1386.006, 17261767.
56. Migliaccio A, Castoria G, Auricchio F. Src-dependent signalling pathway regulation by sex-steroid hormones: therapeutic implications. Int J Biochem Cell Biol 2007, 39:1343-1348. 10.1016/j.biocel.2006.12.009, 17329144.
57. Auricchio F, Migliaccio A, Castoria G. Sex-steroid hormones and EGF signaling in breast and prostate cancer cells: targeting the association of Src with steroid receptors. Steroids 2008, 73:880-884. 10.1016/j.steroids.2008.01.023, 18342899.
58. Levin ER. Plasma membrane estrogen receptors. Trends Endocrinol Metab 2009, 20:477-482. 10.1016/j.tem.2009.06.009, 19783454.
59. Wetherill YB, Akingbemi BT, Kanno J, McLachlan JA, Nadal A, Sonnenschein C, Watson CS, Zoeller RT, Belcher SM. In vitro molecular mechanisms of bisphenol A action. Reprod Toxicol 2007, 24:178-198. 10.1016/j.reprotox.2007.05.010, 17628395.
60. Dong S, Terasaka S, Kiyama R. Bisphenol A induces a rapid activation of Erk1/2 through GPR30 in human breast cancer cells. Environ Pollut 2011, 159:212-218. 10.1016/j.envpol.2010.09.004, 20875696.
61. Tennant MK, Hill DS, Eldridge JC, Wetzel LT, Breckenridge CB, Stevens JT. Chloro-s-triazine antagonism of estrogen action: limited interaction with estrogen receptor binding. J Toxicol Environ Health 1994, 43:197-211. 10.1080/15287399409531915, 7932849.